Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,187
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Lynparza 100 mg film-coated tablets, AZD2281, AZD2281, AZD2281
AstraZeneca AB
solid tumors
1 trial -
MYCOPHENOLATE MOFETIL, INFLIXIMAB, Rilvegostomig, Rilvegostomig, volrustomig, CARBOPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion., Datopotamab deruxtecan, AZD7789
AstraZeneca AB
Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
1 trial -
PET study of changes in [11C]AZ14132516 uptake following administration of multiple AZD7798 doses to patients with Crohn’s disease.
AstraZeneca AB
Crohn's disease
1 trial -
Phase 1 Study of AZD9833 Alone or in Combination in Women with Advanced Breast Cancer
AstraZeneca AB
"Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer"
1 trial -
Phase Ib Randomised, Placebo-controlled, Double-blind, Multicentre Study to Assess the Effects and Safety of AZD5462 on top of Dapagliflozin in Participants with Heart Failure and Moderate Renal Impairment
AstraZeneca AB
Moderate Renal Impairment, Heart Failure
1 trial -
TRUQAP 200 mg film-coated tablets, Faslodex 250 mg solution for injection., TRUQAP 160 mg film-coated tablets, PACLITAXEL, IMFINZI 50 mg/mL concentrate for solution for infusion., Capecitabine Accord 500 mg film-coated tablets, Capecitabine Accord 150 mg film-coated tablets, DS-8201a, Arimidex® 1 mg film-coated tablets
AstraZeneca AB
Metastatic Breast Cancer
1 trial -
Calquence 100 mg film-coated tablets, Calquence 100 mg film-coated tablets
AstraZeneca AB
Chronic Lymphocytic Leukaemia and Moderate to Severe Cardiac Impairment
1 trial -
DS-8201a
AstraZeneca AB
Treatment of patients with HER2-positive breast cancer with or without brain metastasis
1 trial -
Placebo for benralizumab for clinical trials is a sterile liquid solution presented in an accessorized prefilled syringe (apfs) for subcutaneous injection., Fasenra 30 mg solution for injection in pre-filled syringe
AstraZeneca AB
Severe eosinophilic asthma
1 trial -
The placebo MDI is formulated as a suspension of spray-dried porous particles (consisting of 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC] and calcium chloride) in a hydrofluoroalkane propellant (HFA-134a). The placebo MDI uses the same excipients as active product but with absence of the active pharmaceutical ingredient (API)., Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension
AstraZeneca AB
Chronic Obstructive Pulmonary Disease
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources